Inactive
Notice ID:2022-68507
Illumina Nextseq 1000 is a benchtop sequencer used for sequencing for a variety of applications such as Small Whole-Genome Sequencing (microbe/virus), Targeted Gene Sequencing (amplicon, gene panel) a...
Illumina Nextseq 1000 is a benchtop sequencer used for sequencing for a variety of applications such as Small Whole-Genome Sequencing (microbe/virus), Targeted Gene Sequencing (amplicon, gene panel) and16S Metagenomic Sequencing. There is currently no other sequencing technology in the market that can provide the required accuracy and high-quality data compared to illumina platform. Currently, we have been using two Illumina Miseqs, one of them is more than eight years old and having multiple issues after the hardware and software upgrade. Thus, more reliable and the latest Nextseq1000 instrument is required to continue generating the high-quality sequencing data and prevent the loss of time and money because of the possible run failures associated with the instruments. In addition, this newly released instrument can produce more amount of data in comparison to the Miseq instruments and it has more flexibilities in selecting the sequencing kits. Proposed Vendor: Illumina Inc., 5200 Illumina Way, San Diego CA 92122-4616 This contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under the authority of FAR 13.106-1(b) and 41 U.S.C. 3304(a)(1). Interested persons may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive quotations. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. Any quotation/response should be emailed to Rebecca Rasool Contract Specialist (CTR), at MSO9@cdc.gov by 1:00PM EST 8/19/2022